Publications of Laurent VROONEN
Bookmark and Share    
Full Text
See detailSystème rénine-angiotensine-aldostérone : bref historique et questionnements face à la pandémie COVID-19
VALDES SOCIN, Hernan Gonzalo ULiege; JOURET, François ULiege; VROONEN, Laurent ULiege et al

in Revue Médicale de Liège. Supplément (2020), 75

The breakthrough of the secrets of hypertension and the renin-angiotensin-aldosterone system (RAAS) is one of the legends of medicine. The first chapter is the one of Tigerstedt’s experiments about renin ... [more ▼]

The breakthrough of the secrets of hypertension and the renin-angiotensin-aldosterone system (RAAS) is one of the legends of medicine. The first chapter is the one of Tigerstedt’s experiments about renin, and Loesch and Gollblatt’s model of renal hypertension. The race to elucidate the mechanisms of angiotensin, angiotensinogen and the angiotensin conversion enzyme cascade, by Braun Menéndez and Page teams, is a second chapter. The puzzle of this elegant cascade is completed by aldosterone isolation by the collaboration of Tait spouses and Tadeus Rechstein. As a corollary of these findings, Conn made the first description of primary hyperaldosteronism. The elucidation of RAAS pathophysiology naturally led to the synthesis of the antihypertensive captopril by Ondetti and Cushman, thereby opening the modern era of ACE inhibitors and ARII blockers. In March 2020, a viral pandemic caused by SARS-Cov-2 ignites the entire planet. This new coronavirus uses the RAAS angiotensin conversion enzyme type 2 (ACE-2) as a gateway. The SARS-CoV-2/ ACE-2 signalling pathway and its pathological effects on the cardio-respiratory and renal system of these patients initiate a new chapter. The interaction of SARS-Cov-2/ ACE-2 axis with anti-hypertensive agents, as well as with ACE-2 activators and ACE-2 homologs, takes a part of an active international study searching for therapeutic targets. This modern research, summarized in this article, will further develop our knowledge of RAAS and, hopefully, will improve the management of COVID-19 patients. [less ▲]

Detailed reference viewed: 121 (18 ULiège)
Full Text
See detailEpidemiology and Management Challenges in Prolactinomas.
VROONEN, Laurent ULiege; Daly, Adrian ULiege; Beckers, Albert ULiege

in Neuroendocrinology (2019)

Clinically relevant pituitary adenomas are present in about 1 per 1000 of the general population and prolactinomas are by far the most common clinical subtype of pituitary adenomas. Usually prolactinomas ... [more ▼]

Clinically relevant pituitary adenomas are present in about 1 per 1000 of the general population and prolactinomas are by far the most common clinical subtype of pituitary adenomas. Usually prolactinomas affect pre-menopausal women and present with typical symptoms of menstrual disturbance and/or galactorrhea. They are generally managed with dopamine agonists to restore fertility and to control symptoms and tumour size. In a subset of prolactinomas, however, management remains challenging. Studies in recent years have identified the factors related to dopamine agonist resistance, such as, male sex, genetic features, and aggressive tumor behaviour. Certain other patient groups represent particular challenges for management, such as pediatric patients and pregnant women. Treatment with dopamine agonists is usually safe and effective, and adverse effects such as clinically relevant cardiac valvular complications and impulse control disorders may occur in isolated instances. A number of important disease characteristics of prolactinomas remain to be explained, such as the difference in sex prevalence before and after menopause, the higher prevalence of macroadenomas in older males and the biochemical mechanisms of resistance to dopaminergic agonists. [less ▲]

Detailed reference viewed: 118 (22 ULiège)
Full Text
See detailLa saga de la rénine et de l'angiotensine: découvertes historiques et perspectives
VALDES SOCIN, Hernan Gonzalo ULiege; VROONEN, Laurent ULiege

Scientific conference (2018, December 03)

Detailed reference viewed: 59 (8 ULiège)
Full Text
See detailEpidemiological, biochemical, genetical aspects of pheochromocytomas and paragangliomas followed in CHU of Liège between 1993 and 2017
PETIGNOT, Sandrine ULiege; VROONEN, Laurent ULiege; HAMOIR, Etienne ULiege et al

in Abstract book - 28th meeting of the Belgian Endocrine Society (2018, October)

Detailed reference viewed: 56 (7 ULiège)
Full Text
See detailEstablishment of reference values for 6 six steroids in serum
LE GOFF, Caroline ULiege; Fabregat Cabello, Neus ULiege; Huyghebaert, Loreen ULiege et al

in Clinical Chemistry and Laboratory Medicine (2017, June)

Detailed reference viewed: 81 (9 ULiège)
Full Text
See detailReference interval determination for serum and urine aldosterone for healthy Belgian population
LE GOFF, Caroline ULiege; Fabregat Cabello, Neus ULiege; Huyghebaert, Loreen ULiege et al

in Clinical Chemistry and Laboratory Medicine (2017, June)

Detailed reference viewed: 48 (5 ULiège)
Full Text
See detailProspective, long-term study of the effect of cabergoline on valvular status in patients with prolactinoma and idiopathic hyperprolactinemia.
VROONEN, Laurent ULiege; Lancellotti, Patrizio ULiege; Garcia, Monica Tome et al

in Endocrine (2016)

Since the 1990's cabergoline has been the treatment of choice in prolactinoma, as it permits rapid and effective hormonal and tumor control in most cases. Evidence of cardiac valvulopathy was demonstrated ... [more ▼]

Since the 1990's cabergoline has been the treatment of choice in prolactinoma, as it permits rapid and effective hormonal and tumor control in most cases. Evidence of cardiac valvulopathy was demonstrated in Parkinson's disease patients treated with dopamine agonists. Retrospective studies in prolactinoma patients treated with cabergoline at lower doses did not show such an effect. However, few prospective data with long-term follow-up are available. The aim of this study was to assess the safety of cabergoline regarding cardiac valvular status during prospective follow-up in patients treated for prolactinoma or idiopathic hyperprolactinemia. We report here a series of 100 patients (71F; median age at diagnosis: 41.5 years) treated with cabergoline for endocrine diseases (prolactinoma n = 89, idiopathic hyperprolactinemia n = 11). All patients underwent complete transthoracic echocardiographic studies at baseline and during long-term prospective surveillance using the same equipment and performed by the same technicians. The median interval between baseline and last follow-up echocardiographic studies while on cabergoline was 62.5 months (interquartile range: 34.75-77.0). The median total duration of cabergoline treatment was 124.5 months (interquartile range: 80.75-188.75) and the median cumulative total dose of cabergoline was 277.8 mg (interquartile range : 121.4-437.8 mg) at last follow-up. We found no clinically relevant alterations in cardiac valve function or valvular calcifications with cabergoline treatment. Our data suggest that findings from retrospective analyses are correct and that cabergoline is a safe chronic treatment at the doses used typically in endocrinology. [less ▲]

Detailed reference viewed: 246 (14 ULiège)
Full Text
See detailFrom guidelines to real daily practice : prolactinoma in pregnancy
VROONEN, Laurent ULiege; Potorac, Iulia ULiege; D'Andréa, S et al

in Annales d'Endocrinologie : 33ème congrès de la Société Française d'Endocrinologie (2016, October)

Detailed reference viewed: 61 (5 ULiège)
Full Text
See detailMaladie de Cushing et kyste de la poche de Rathke : un défi diagnostique
VROONEN, Laurent ULiege; KREUTZ, Julie ULiege; Potorac, Iulia ULiege et al

in Annales d'Endocrinologie : 33ème congrès de la Société Française d'Endocrinologie (2016, October)

Detailed reference viewed: 119 (7 ULiège)
Full Text
See detailA new clinical presentation of a non-so-rare disease, the Di George syndrome
VROONEN, Laurent ULiege; D'Andrea, S; Tome, M et al

in Annales d'Endocrinologie : 33ème congrès de la Société Française d'Endocrinologie (2016, October)

Detailed reference viewed: 49 (3 ULiège)
Full Text
See detailUtilisation de la cabergoline dans le traitement palliatif de la maladie de Cushing : l'étude Frenchcab
Ferriere, A; Cortet, C; Chanson, P et al

in Annales d'Endocrinologie : 33ème congrès de la Société Française d'Endocrinologie (2016, October)

Detailed reference viewed: 71 (1 ULiège)
Full Text
See detailThe role of tyrosin kinase inhibitors in a MEN2B patient with metastatic medullary thyroid carcinoma
Tome, M; Tomas, M-H; VROONEN, Laurent ULiege et al

in Symposium "Perspectives in Endocrinology" - Congresses Highlights 2012: ECE Firenze, ENDO Houston, ESPE Leipzig, SFE Toulouse, IWMEN Liège (2013)

Detailed reference viewed: 68 (3 ULiège)
Full Text
See detailA prospective study of cardiac valvular status in patients treated with cabergoline for endocrine disease
VROONEN, Laurent ULiege; LANCELLOTTI, Patrizio ULiege; Tome, M et al

in Symposium "Perspectives in Endocrinology" - Congresses Highlights 2012: ECE Firenze, ENDO Houston, ESPE Leipzig, SFE Toulouse, IWMEN Liège (2013)

Detailed reference viewed: 58 (12 ULiège)
Full Text
See detailA prospective study of cardiac valvular status in patients treated with cabergoline for Endocrine Disease
VROONEN, Laurent ULiege; Lancellotti, Patrizio ULiege; Tome Garcia, M et al

in Annales d'Endocrinologie (2012, April), 73(2), 148

Detailed reference viewed: 38 (5 ULiège)
Full Text
See detailClinical characterization of cabergoline resistant prolactinomas : a multicenter experience on 92 patients
VROONEN, Laurent ULiege; Jaffrain Rea, ML; PETROSSIANS, Patrick ULiege et al

in Annales d'Endocrinologie (2012, April), 73(2), 153

Detailed reference viewed: 65 (7 ULiège)